Dr Tolaney speaks with ecancertv at the 2016 San Antonio Breast Cancer Symposium about results from a phase Ib/II study of anti-PD-1 pembrolizumab with eribulin mesylate, a microtubule growth inhibitor, for metastatic breast cancer patients.

She describes the benefits to patients, with a complete and objective responses recorded at this interim analysis, which she notes as being independent of PD-L1 positivity in samples.

Dr Tolaney considers the toxicity profile of checkpoint inhibitory therapy, and the broader future of immunotherapy for breast cancer.